+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years - 90Years
FEMALE
ID07780955

Evaluating Cryotherapy to Reduce Nerve Damage from Weekly Paclitaxel Chemotherapy in Female Breast Cancer Patients

Led by Azienda Sanitaria dell'Alto Adige · Updated on 2026-08-24

144

Participants Needed

4

Research Sites

13 weeks

Total Duration

AI-Summary

What This Trial Is About

This research aims to evaluate whether acral cryotherapy can reduce the incidence and severity of chemotherapy-induced peripheral neuropathy CIPN in female breast cancer patients receiving weekly paclitaxel-based chemotherapy. CIPN is a common side effect caused by nerve damage during chemotherapy, which can affect quality of life and lead to treatment changes or stopping treatment. The study compares patients receiving cryotherapy with those receiving standard care without cryotherapy. Participants in the cryotherapy group will use the Hilotherm Chemocare device that delivers continuous-flow cold at 15C to the hands and feet. This cooling starts 15 minutes before chemotherapy infusion, continues during the infusion, and lasts 15 minutes after. The control group will receive standard care without cryotherapy. The study involves randomized assignment to either group. During chemotherapy and for one year after completing treatment, participants will undergo repeated assessments including neurological exams, nerve conduction studies, patient questionnaires on quality of life, and blood tests. Additional blood samples will be collected at two time points to analyze biomarkers of nerve damage. The main outcome measured is the change in neuropathy score from before treatment to six months after chemotherapy ends.

CONDITIONS

Brief Title

Multimodal Assessment of Cryotherapy for Paclitaxel-Induced Neuropathy

Research Team

M

Mattia Bergamo, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here